Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod plus tofacitinib versus tofacitinib alone for maintenance and dose reduction in rheumatoid arthritis
ChiCTR2200062645Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of iguratimod and tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: Clinical remission rate at 96 weeks and DAS28-ESR remission rate at 48 and 72 weeks. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
iguratimodtofacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2200062645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062645.